Conferences \ Lab-on-a-Chip & Microfluidics World Congress 2017 \ Lab-on-a-Chip and Microfluidics: Companies, Technologies and Commercialization \ Agenda \ Xin Han |
Register | Login |
Microfluidic Biotechnology Enables CRISPR-Cas9 System for Gene Therapy and Cancer Biomarker DiscoveryWednesday, 4 October 2017 at 09:00 Add to Calendar ▼2017-10-04 09:00:002017-10-04 10:00:00Europe/LondonMicrofluidic Biotechnology Enables CRISPR-Cas9 System for Gene Therapy and Cancer Biomarker DiscoverySELECTBIOenquiries@selectbiosciences.com The CRISPR (clustered regularly interspaced short palindromic repeats)-Cas (CRISPR-associated) nuclease system represents an efficient tool for genome editing and gene function analysis. Integrated microfluidic chips have been well designed with micro and nanostructures to rapidly distinguish cell morphology and dynamics, which are uniquely advantageous in improving efficiency of CRISPR based delivery and screening. Here we combined the two unique technologies to facilitate cancer biomarker discovery and gene therapy. |